Comparative risk of amyloid-related imaging abnormalities with anti-amyloid-β monoclonal antibodies: A systematic review and penalized likelihood network meta-analysis of randomized trials.
J Alzheimers DisJul 11, 2026 (epub)
Arkansh Sharma, Vinay Suresh, Pavan Raju Kola et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the risk of amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid-β monoclonal antibodies in Alzheimer's disease. Analyzing 22 randomized trials with up to 23,120 participants, the study found a pooled ARIA-E prevalence of 6.8% and ARIA-H of 15.8%. Anti-amyloid-β therapy significantly increased the odds of ARIA-E (OR 7.93) and ARIA-H (OR 1.87) compared to placebo.
Key findings
- Pooled prevalence of ARIA-E was 6.8% and ARIA-H was 15.8%.
- Anti-amyloid-β therapy increased odds of ARIA-E by OR 7.93 compared to placebo.
- ARIA-H risk increased with anti-amyloid-β therapy, with an OR of 1.87.
- APOE ε4 carriage significantly elevated ARIA-E (OR 2.28) and ARIA-H (OR 2.07) risk.
Why it matters
Understanding the comparative risks of ARIA associated with different anti-amyloid-β therapies is crucial for clinicians to make informed decisions about treatment options and monitoring strategies in Alzheimer's disease.